Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.

Biogen Inc. (BIIB) Down 1.4% Since Last Earnings Report: Can It Rebound?

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal

Denali (DNLI) posts earnings in the fourth quarter of 2020 due to collaboration revenues from Biogen.

Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates

Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.

AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod

AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.

The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte

The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte

Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates

Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.

Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to Q4 Earnings?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.

Biogen (BIIB) Q4 Earnings Miss, Revenues Surpass Estimates

Biogen's (BIIB) earnings lag estimates in the fourth quarter of 2020, while revenues surpass the same. Tecfidera generics continues to hurt sales. The company provides revenues guidance for 2021.

Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More

Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.

Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

Biogen Inc. (BIIB) Misses Q4 Earnings Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of -7.10% and 1.22%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports fourth-quarter earnings.

Why the Earnings Surprise Streak Could Continue for Biogen Inc. (BIIB)

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study

Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.

The Zacks Analyst Blog Highlights: PayPal, Exxon Mobil, Goldman Sachs, Charter Communications and Biogen

The Zacks Analyst Blog Highlights: PayPal, Exxon Mobil, Goldman Sachs, Charter Communications and Biogen

Sheraz Mian headshot

Top Research Reports for PayPal, Exxon Mobil & Goldman Sachs

Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), Exxon Mobil (XOM), and Goldman Sachs (GS).

Ekta Bagri headshot

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.

Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day

Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day

Lilly's (LLY) Alzheimer's Drug Promising in Mid-Stage Study

Lilly (LLY) announces data from a phase II study on its Alzheimer's disease candidate, donanemab, which shows slowing of cognitive decline.

Apple (AAPL), Biogen to Track Cognitive Health via Wearables

Apple (AAPL) is collaborating with Biogen to test whether the Apple Watch and iPhone can collect and transmit biometric data on cognitive performance.

AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies

AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.

AbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies

AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.